We are live on ! Find out more
GILD icon

Gilead Sciences

1,528 hedge funds and large institutions have $79.3B invested in Gilead Sciences in 2018 Q3 according to their latest regulatory filings, with 91 funds opening new positions, 539 increasing their positions, 693 reducing their positions, and 72 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more first-time investments, than exits

New positions opened: 91 | Existing positions closed: 72

21% more funds holding in top 10

Funds holding in top 10: 4757 (+10)

9% more capital invested

Capital invested by funds: $72.7B → $79.3B (+$6.6B)

0% more funds holding

Funds holding: 1,5231,528 (+5)

0.31% more ownership

Funds ownership: 79%79.31% (+0.31%)

22% less repeat investments, than reductions

Existing positions increased: 539 | Existing positions reduced: 693

27% less call options, than puts

Call options by funds: $1.21B | Put options by funds: $1.66B

Holders
1,528
Holders Change
+5
Holders Change %
+0.33%
% of All Funds
34.93%
Holding in Top 10
57
Holding in Top 10 Change
+10
Holding in Top 10 Change %
+21.28%
% of All Funds
1.3%
New
91
Increased
539
Reduced
693
Closed
72
Calls
$1.21B
Puts
$1.66B
Net Calls
-$449M
Net Calls Change
+$117M
Name Holding Trade Value Shares
Change
Change in
Stake
RJFSA
251
Raymond James Financial Services Advisors
Florida
$20.3M +$3.03M +40,087 +18%
CBOA
252
Commonwealth Bank of Australia
Australia
$20.2M -$397K -5,262 -2%
GH
253
GAM Holding
Switzerland
$20.2M +$153K +2,020 +0.8%
NIM
254
Nexus Investment Management
Ontario, Canada
$20.2M +$2.42K +32 +0%
SEI Investments
255
SEI Investments
Pennsylvania
$20.1M -$11.1M -147,483 -36%
Commonwealth Equity Services
256
Commonwealth Equity Services
Massachusetts
$20.1M -$2.09M -27,609 -10%
DP
257
Dearborn Partners
Illinois
$20M +$5.37M +71,145 +38%
BTS
258
BB&T Securities
Virginia
$19.9M -$315K -4,171 -2%
Marshall Wace
259
Marshall Wace
United Kingdom
$19.9M +$18.3M +241,875 +1,562%
PP
260
PDT Partners
New York
$19.8M +$1.36K +18 +0%
PR
261
Payden & Rygel
California
$19.7M +$242K +3,200 +1%
MNG
262
Manning & Napier Group
New York
$19.2M +$1.14M +15,062 +6%
XK
263
Xact Kapitalforvaltning
Sweden
$19.1M -$1.27M -16,861 -6%
BFM
264
Boston Financial Management
Massachusetts
$19.1M +$3.68M +48,773 +25%
QI
265
QS Investors
New York
$19M -$461K -6,107 -2%
UCFA
266
United Capital Financial Advisors
Texas
$19M -$23.7M -314,379 -56%
ZIG
267
Zurich Insurance Group
Switzerland
$18.9M +$2.03M +26,871 +12%
URS
268
Utah Retirement Systems
Utah
$18.6M +$83.1K +1,100 +0.5%
MAM
269
Majedie Asset Management
United Kingdom
$18.4M -$1.32M -17,436 -7%
MLICM
270
Metropolitan Life Insurance Company (MetLife)
New York
$18.3M -$503K -6,663 -3%
FRM
271
Foundation Resource Management
Arkansas
$18.2M -$62.7K -830 -0.4%
HCM
272
Howland Capital Management
Massachusetts
$18.1M -$1.56M -20,648 -8%
OA
273
Oak Associates
Ohio
$18.1M +$1.97M +26,103 +13%
NB
274
Norinchukin Bank
Japan
$18M +$1.42M +18,868 +9%
Public Employees Retirement Association of Colorado
275
Public Employees Retirement Association of Colorado
Colorado
$18M -$18.4K -243 -0.1%

GILD Hedge Fund Activity: Q3 2018 in Review

1,528 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q3 2018, worth a combined $79.3B — up 9.1% from $72.7B a quarter earlier.

Buyers outnumbered sellers: 91 funds opened new GILD positions and 72 closed out — a net gain of 19 holders — while 539 added to existing stakes and 693 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $968M. The largest seller was Parnassus Investments, cutting an estimated $683M.

  • 1,528 institutional investors held Gilead Sciences (GILD) as of Q3 2018, up from 1,523 in Q2 2018.
  • Funds reported $79.3B of Gilead Sciences stock for Q3 2018, up 9.1% quarter-over-quarter.
  • 91 funds opened new Gilead Sciences positions in Q3 2018 and 72 closed out, a net change of +19 holders.
  • The largest Gilead Sciences buyer in Q3 2018 was Capital Research Global Investors, an estimated $968M added.
  • The largest Gilead Sciences seller in Q3 2018 was Parnassus Investments, an estimated $683M sold.

Based on aggregated 13F filings for Q3 2018.